Resultats de la cerca - Marie O’Farrell

  • Mostrar 1 - 12 resultats de 12
Refinar resultats
  1. 1
    Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target

    Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target per Douglas Buckley, Gregory Duke, Timothy S. Heuer, Marie O’Farrell, Allan S. Wagman, William McCulloch, George Kemble

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

    FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models per Marie O’Farrell, G M Duke, R. Webster Crowley, Douglas Buckley, Eduardo B. Martins, Dipankar Bhattacharya, Scott L. Friedman, George Kemble

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

    Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells per Kevin Yee, Marcus M. Schittenhelm, Anne-Marie O'Farrell, Ajia Town, Laura McGreevey, Troy Bainbridge, Julie M. Cherrington, Michael C. Heinrich

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

    Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification per Samuel E. DePrimo, Lily Wong, Deepak Khatry, Susan L Nicholas, William C. Manning, Beverly D. Smolich, Anne-Marie O’Farrell, Julie M. Cherrington

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

    Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial per Rohit Loomba, Pierre Bédossa, Katharine Grimmer, George Kemble, Eduardo B. Martins, William McCulloch, Marie O’Farrell, Wen-Wei Tsai, Jose Cobiella, Eric Lawitz, Madhavi Rudraraju, Stephen A. Harrison

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Therapeutic efficacy of FASN inhibition in preclinical models of HCC

    Therapeutic efficacy of FASN inhibition in preclinical models of HCC per Haichuan Wang, Yi Zhou, Hongwei Xu, Xue Wang, Yi Zhang, Runze Shang, Marie O’Farrell, Stephanie Roessler, Carsten Sticht, Andreas Stahl, Matthias Evert, Diego F. Calvisi, Yong Zeng, Xin Chen

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model

    p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model per Hoi Yee Chow, Adrian M. Jubb, Jennifer N. Koch, Zahara M. Jaffer, Dina Stepanova, David A. Campbell, Sergio G. Durón, Marie O’Farrell, Kathy Q. Cai, Andres J. Klein–Szanto, J. Silvio Gutkind, Klaus P. Hoeflich, Jonathan Chernoff

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

    SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo per Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen, Theresa J. Ngai, Sharianne G. Louie, Kevin Yee, Lily Wong, Weiru Hong, Leslie B. Lee, Ajia Town, Beverly D. Smolich, William C. Manning, Lesley Murray, Michael C. Heinrich, Julie M. Cherrington

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors per Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

    SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes per Francis J. Giles, Alison Stopeck, Lewis R. Silverman, Jeffrey E. Lancet, Maureen Cooper, Alison L. Hannah, Julie M. Cherrington, Anne-Marie O'Farrell, Helene A. Yuen, Sharianne G. Louie, Weiru Hong, Jorge E. Cortés, Srđan Verstovšek, Maher Albitar, Susan O’Brien, Hagop M. Kantarjian, Judith E. Karp

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

    TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial per Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, Julio Gutiérrez, Robert G. Perry, James F. Trotter, Robert S. Rahimi, Stephen A. Harrison, Veeral Ajmera, Jeffrey D. Wayne, Marie O’Farrell, William McCulloch, Katharine Grimmer, Mary E. Rinella, Vincent Wai‐Sun Wong, Vlad Ratziu, Gregory J. Gores, Brent A. Neuschwander‐Tetri, George Kemble

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use

    Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use per Anna Worthmann, Julius Ridder, Sharlaine Piel, Ioannis Evangelakos, Melina Musfeldt, Hannah Voß, Marie O’Farrell, Alexander W. Fischer, Sangeeta Adak, Monica Sundd, Hasibullah Siffeti, Friederike Haumann, Katja Kloth, Tatjana Bierhals, Markus Heine, Paul Pertzborn, Mira Pauly, Julia-Josefine Scholz, Suman Kundu, Marceline M. Fuh, Axel Neu, Klaus Tödter, Maja Hempel, Uwe Knippschild, Clay F. Semenkovich, Hartmut Schlüter, Jöerg Heeren, Ludger Scheja, Christian Kubisch, Christian Schlein

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: